转移性膀癌的现实世界治疗序列和整体存活率:STATES-膀研究
Fabien Moinard-Butot1, Jean-Baptiste Barbe-Richaud1, Edwige Baudry2
1Department of Medical Oncology, University Hospital of Strasbourg, Strasbourg, France.
Urologic oncology
|March 1, 2026
概括
现实世界的数据表明,以为基础的化疗,其次是阿维卢马布维护,改善了转移性尿路细胞癌 (mUC) 的整体存活率. 在治疗线之间发生了显著的患者消耗,特别是那些表现不佳的患者.
科学领域:
- 医学瘤学 医学瘤学
- 尿癌研究 尿癌研究
- 临床试验分析
背景情况:
- 转移性尿路细胞癌 (mUC) 的治疗环境正随着新疗法而发展.
- 标准治疗通常涉及基于的化疗 (PBC),其次是免疫检查点抑制剂 (ICI).
- 有限的现实世界数据存在于治疗顺序和耗尽在mUC.
研究的目的:
- 分析真实世界治疗序列和mUC患者的结果.
- 评估跨治疗线的整体生存率 (OS) 和消耗率.
- 为了评估PBC的有效性,然后再进行Avelumab的维护.
主要方法:
- 来自法国4个瘤中心的180名mUC患者的回顾性分析 (2020年1月-2023年12月).
- 纳入标准:至少一轮的第一线PBC.
- 使用Kaplan-Meier方法评估OS,治疗序列和消耗.
主要成果:
- 平均生存期为22.4个月. 接受PBC和avelumab维持治疗的患者的生存状况有所改善 (29.0个月),而非响应者 (15.6个月).
- 观察到显著的消耗:只有64%的患者接受了二线治疗,25%的患者获得了三线治疗.
- 糟糕的绩效状态 (ECOG 2-3) 与明显更糟糕的结果 (7.2 个月的 OS) 相相关.
结论:
- 当代的mUC治疗序列显示了现实世界的有效性.
- 治疗线之间的显著消耗需要优化治疗策略.
- 早期使用有效药物至关重要,特别是对于表现不佳的患者.
相关概念视频
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...